Impact of viral eradication with sofosbuvir‐based therapy on the outcome of post‐transplant hepatitis C with severe fibrosis
- 20 July 2016
- journal article
- Published by Wiley in Liver International
- Vol. 37 (1), 62-70
- https://doi.org/10.1111/liv.13193
Abstract
At about 1 year from the completion of successful sofosbuvir-based therapy, patients with post-LT HCV and severe fibrosis experienced a long-term liver function improvement accompanied by a regression of fibrosis stage in half of them.This publication has 22 references indexed in Scilit:
- Early reduced liver graft survival in hepatitis C recipients identified by two combined genetic markersTransplant International, 2016
- Interferon‐free therapy for genotype 1 hepatitis C in liver transplant recipients: Real‐world experience from the hepatitis C therapeutic registry and research networkLiver Transplantation, 2015
- EASL Recommendations on Treatment of Hepatitis C 2015Journal of Hepatology, 2015
- Sofosbuvir compassionate use program for patients with severe recurrent hepatitis C after liver transplantationHepatology, 2014
- Safety and efficacy of protease inhibitors to treat hepatitis C after liver transplantation: A multicenter experienceJournal of Hepatology, 2013
- Evolution of indications and results of liver transplantation in Europe. A report from the European Liver Transplant Registry (ELTR)Journal of Hepatology, 2012
- Viral Hepatitis in Liver TransplantationGastroenterology, 2012
- Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirinJournal of Hepatology, 2008
- Non-invasive evaluation of liver fibrosis using transient elastographyJournal of Hepatology, 2008
- FIB-4: An inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotestHepatology, 2007